FemRx' Opera Star cleared for US marketing
This article was originally published in Clinica
Gynaecology specialist FemRx has received 510(k) clearance for its minimally invasive alternative to hysterectomy, the Opera Star system. The Out-Patient Endometrial Resection/Ablation device treats abnormal uterine bleeding in most patients without the need for an incision (see Clinica No 696, p 10). The system consists of a Specialised Tissue Aspirating Resectoscope which enables gynaecological surgeons to resect and ablate the endometrial lining and remove fibroids while continuously aspirating tissue for pathological evaluation.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.